Evidence map›Paper›PMID 35918148›Full record

ArticleJournal of the American Society of Nephrology : JASN2022

Decorating Histones in Polycystic Kidney Disease.

Harini Ramalingam, Vishal Patel

Open access · greenAbstract readEditorialComment
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. How Does ADPKD Severity Differ Between Family Members?Kidney international reports · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Harini RamalingamDivision of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
The University of Texas Southwestern Medical Center · US

Funding

The impact of RNA chemical modifications on polycystic kidney disease progressionR01DK102572 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PATEL, VISHAL · 2015 to 2024
$3.5M
PKD1 derepression as a potential therapy for Polycystic Kidney DiseaseR01DK133186 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Vishal Patel · 2022 to 2026
$2.7M
NIDDK NIH HHS R01 DK102572NIDDK NIH HHS R01 DK133186
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Polycystic Kidney, Autosomal DominantPolycystic Kidney DiseasesHistonesHumansKidneyHistonesADPKDcrotonylationepigeneticsgene expressionhistonesphase separation

Identifiers

PMID35918148
PMCPMC9529189
OpenAlexW4289518298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.